A patient with a history of HIV presents to the ED with a 3- to 4-week history of vomiting and testicle pain. Can you make the diagnosis?
Black cancer patients are less likely than their White counterparts to receive shorter radiotherapy regimens, a study suggests.
Consolidation with up to 8 cycles of brentuximab vedotin plus nivolumab appears active in high-risk, relapsed/refractory Hodgkin lymphoma.
Serial stereotactic body radiation therapy directed by PET using novel radiotracers may offer clinical benefits in patients with oligometastatic prostate cancer.
Chronic convection-enhanced delivery of topotecan was feasible and well tolerated in patients with recurrent glioblastoma.
Patients with comorbidities are not routinely included in clinical trials.
From 2020 to 2021, COVID-19-related deaths increased among younger people.
Residential racial and economic segregation across US counties is associated with higher cancer mortality, a study suggests.
More than one-third of patients with non-small cell lung cancer treated upfront with nivolumab plus ipilimumab were alive at 3 years.
Using ctDNA testing to predict recurrence and guide therapy in triple-negative breast cancer is challenging, according to researchers.
After adjustment for confounding variables, the risk of endometrial cancer was increased almost 4-fold with tamoxifen treatment.
Researchers demonstrated the feasibility of remote cognitive assessments in patients with hematologic malignancies.
Patients with MCL and CNS involvement had superior survival when treated with ibrutinib rather than chemotherapy.
Breast cancer survivors have an increased risk of breast implant-associated ALCL, but the absolute risk is “extremely low,” according to researchers.
New data show that, in the last 2 decades, the incidence of cervical cancer in the United States has declined or remained stable for most age groups.
A more than 2-fold increased risk of prostate cancer was seen for patients whose first melanoma diagnosis was 10 to 15 years before study recruitment.
Recurrence of bladder cancer after radical cystectomy can occur up to 4 years after surgery, a study suggests.
Adding gilteritinib to azacitidine did not improve survival outcomes in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia.
Among patients who did not undergo autologous stem cell transplant, 52.7% advanced to second-line treatment.
The prior authorization process can delay cancer care, leading to disease progression and death, according to a survey of ASCO members.
The incidence of stage I lung cancer increased between 2010 and 2017, according to data from more than 1.4 million US patients with lung cancer.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Patients who underwent robotic liver resection had shorter hospital stays and were less likely to be admitted to the ICU than patients who underwent open liver resection.
Adjuvant pembrolizumab improved quality of life when compared with ipilimumab or high-dose interferon α 2b.
The FDA has issued a complete response letter to Spectrum Pharmaceuticals regarding the new drug application for poziotinib.
Roughly half of hospitals accredited by the ACS-CoC failed to disclose the cost of 5 common cancer surgeries, researchers found.
Adding an autologous tumor lysate-loaded dendritic cell vaccine to standard care improves survival in patients with glioblastoma, a phase 3 study suggests.
Young adult survivors of pediatric cancer experience significant premature aging, a retrospective study suggests.
Homeopathic treatment may improve quality of life and survival among patients with stage III-IV non-small cell lung cancer who are receiving chemotherapy.
In a survey of more than 1000 adults, 83% said they are unaware of the signs or symptoms of pancreatic cancer.
About 40% of patients with lower-risk myelodysplastic syndromes die of the disease within 5 years, a study suggests.
Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
The number of new lung cancer cases decreased 11% over the last 5 years.
This is the first study to assess the role of metastasis-directed therapy in solitary metastatic oligorecurrent prostate cancer in the absence of systemic therapy.
Researchers found that 56% of cancer trials recruited from low- or middle-income countries.
A prospective study compared aprepitant with desloratadine for the relief of treatment-induced pruritus in patients with lung cancer treated with EGFR-TKIs.
Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells.
Researchers are conducting a phase 2 study to compare trastuzumab-based treatment regimens in patients with advanced HER2+ breast cancer.
Researchers are conducting a phase 1 study to test capecitabine in combination with cemiplimab in patients with HR+ metastatic breast cancer.
Researchers are conducting a phase 2 study to determine if ctDNA can be used to guide treatment in patients with ER+, HER2- breast cancer at high risk of recurrence.
Researchers are conducting a phase 2 study to test the safety and efficacy of durvalumab in combination with trastuzumab and pertuzumab for HER2-enriched breast cancer.
While the rate of late-stage NSCLC diagnosis is improving, more needs to be done to increase survival rates. Are there outside factors that affect the stage at diagnosis, and what can we learn from them?
Patients with Medicare Advantage insurance plans have an increased risk of death after certain cancer surgeries, a study suggests.
Multigene panel testing in a large cohort of patients with colorectal cancer revealed a high rate of clinically actionable genetic variants.
The incidence of Kaposi sarcoma is increasing among Black men and decreasing among White men in the United States, a study suggests.
Screening for breast, cervical, and colorectal cancer decreased from prepandemic levels in early 2020, rebounded in late 2020, and decreased again in 2021.
The new dosing option was approved based on data from a phase 2/3 trial.
Red flags include pharmacies that do not require a doctor’s prescription or have a licensed pharmacist to answer questions.
Most recent phase 3 trials of patients with newly diagnosed glioblastoma have shown no significant improvement in overall survival with the experimental treatment.
Deaths among patients with primary malignant brain tumors are on the rise in the United States, data suggest.
Patients with glioma do not have an increased risk of SARS-CoV-2 infection or worse outcomes from COVID-19, a single-center study suggests.
Children and adolescents with medulloblastoma frequently suffer from neuroophthalmological sequelae, a single-center study suggests.
Researchers say they have identified a molecular signature that can be used to predict outcomes of regorafenib treatment in patients with recurrent glioblastoma.
Among glioblastoma patients, women may derive more benefit from immunotherapy than men, research suggests.
Patterns of relapse are similar in patients with standard-risk and high-risk medulloblastoma, a review suggests.
Nearly a third of patients with high-grade glioma who were prescribed opioids after surgery continued to take them beyond the perioperative setting.
VAL-083 in combination with radiotherapy is safe and active in patients with newly diagnosed MGMT-unmethylated glioblastoma, a phase 2 trial suggests.
There are several steps health care providers can take to help patients with CNS cancers navigate the disability application process.
Adding interferon-α to adjuvant temozolomide can prolong overall survival in patients with high-grade glioma, a phase 3 trial suggests.
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
Tovorafenib produced responses in young patients with progressive or recurrent BRAF-altered low-grade glioma in a phase 2 trial.
The sequence of treatment with rolapitant and ondansetron does not appear to impact chemoradiation-induced nausea and vomiting.
About 1 in 10 patients with high-grade glioma had a palliative care consultation before the end-of-life phase, researchers found.
Axillary radiotherapy can replace axillary lymph node dissection in patients with sentinel node-positive early breast cancer, according to researchers.
A systematic review of clinical practice guidelines revealed substantial variation in recommendations for follow-up after initial treatment for keratinocyte carcinoma.
None of the patients had grade 3 or higher acute radiation toxicity.
Breast cancer survivors who were active or moderately active had significantly reduced risk of death.
Adding atezolizumab to obinutuzumab and bendamustine does not improve progression-free survival and carries an increased risk of adverse events, a study suggests.
An article describes inadequate oversight related to the development of COVID-19 vaccines and predating the pandemic.
Non-Hispanic Black patients are less likely than Hispanic or non-Hispanic White patients to receive guideline-recommended treatment for ovarian cancer.
Adding tremelimumab and durvalumab to chemotherapy improves progression-free survival and overall survival in patients with metastatic non-small cell lung cancer, phase 3 data suggest.
Results of a phase 3 trial suggest
18F-NaF PET-CT is more effective than 99mTc-MDP SPECT for detecting bone metastasis in patients with breast or prostate cancer.
Fifteen months of bevacizumab should remain the standard for patients with ovarian cancer receiving chemotherapy after cytoreductive surgery, researchers say.
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
The yearly switch to daylight saving time has been linked to increased odds for heart problems, accidents, and mood disorders.
Reinfection increases the risk of death, hospitalization, and incident sequelae, regardless of vaccination status.
The COVID-19 pandemic has hindered the early diagnosis and treatment of cancer, and this may have set back cancer outcomes by almost a decade in Europe, a new report suggests.
Bariatric surgery may reduce the risk of pancreatic cancer in patients with obesity who are younger than 50 years of age, a study suggests.
As many as 1 in 10 patients with appendix cancer may carry an inherited gene sequence variation associated with cancer susceptibility, a study suggests.
The approval was based on data from the SORAYA trial.
The decision to restrict the indication follows an FDA review of the phase 3 ENGOT-OV16/NOVA trial.
Study results suggest that tumor debulking does not benefit patients undergoing radical cystectomy.
Common symptoms occurring 3 or more months after SARS-CoV-2 infection differ between adults and children/adolescents.
As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.
Dose-dense adjuvant chemotherapy improves disease-free survival in high-risk early breast cancer, according to updated results from the GIM2 trial.
Researchers have identified factors associated with survival outcomes in NSCLC patients treated with immunotherapy or immunochemotherapy.
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced the risk of death by 67%.
Acupuncture can reduce aromatase inhibitor-related joint pain in women with early breast cancer, a study suggests.
Adding abemaciclib to adjuvant endocrine therapy improves outcomes in patients with high-risk early breast cancer, data suggest.
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
The approval was based on data from the phase 3 POSEIDON study.
The approval was based on data from the open-label phase 3 AHOD1331 trial.
The authorization was supported by data from the phase 3 SAVE-MORE trial.
Two new studies shed light on the complexity of preventing subsequent breast cancer events in patients with ductal carcinoma in situ.
None of the YouTube or TikTok videos analyzed contained both high-quality and accurate information on prostate cancer screening.
Margetuximab does not provide an overall survival benefit over trastuzumab in patients with previously treated, HER2-positive breast cancer, a phase 3 trial suggests.
The use of oncology hospitalists can reduce readmission rates and improve discharge to hospice, a study suggests.